title: Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia.
abstract: OBJECTIVE
  This study investigates whether achieving complete remission (CR) with undetectable minimal residual disease (MRD) after allogeneic stem cell transplantation (allo-SCT) for chronic lymphocytic leukemia (CLL) affects outcome.
  
  
  METHODS
  We retrospectively studied 46 patients transplanted for CLL and evaluated for post-transplant MRD by flow cytometry.
  
  
  RESULTS
  At transplant time, 43% of the patients were in CR, including one with undetectable MRD, 46% were in partial response, and 11% had refractory disease. After transplant, 61% of the patients achieved CR with undetectable MRD status. By multivariate analysis, reaching CR with undetectable MRD 12 months after transplant was the only factor associated with better progression-free survival (P = 0.02) and attaining undetectable MRD, independently of the time of negativity, was the only factor that correlated with better overall survival (P = 0.04).
  
  
  CONCLUSIONS
  Thus, achieving undetectable MRD status after allo-SCT for CLL is a major goal to improve post-transplant outcome.
authors.affiliation: Hématologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.|Sorbonne Universités, UPMC Univ Paris 06, GRC n°11, GRECHY, Paris, France.
authors.forename: Caroline
authors.initials: C
authors.lastname: Algrin
authors.affiliation: Unité de Recherche Clinique, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Golmard
authors.affiliation: Hématologie, Centre Hospitalo-Universitaire (CHU) E. Herriot, Lyon, France.
authors.forename: Mauricette
authors.initials: M
authors.lastname: Michallet
authors.affiliation: Hématologie, CHU de Caen, Caen, France.
authors.forename: Oumedaly
authors.initials: O
authors.lastname: Reman
authors.affiliation: Hématologie, CHU de Toulouse, Toulouse, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Huynh
authors.affiliation: Hématologie, CHU de Nancy, Nancy, France.
authors.forename: Aurore
authors.initials: A
authors.lastname: Perrot
authors.affiliation: Hématologie, CHU de Nice, Nice, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Sirvent
authors.affiliation: Laboratoire d'Hématologie, CHU E. Herriot, Lyon, France.
authors.forename: Adriana
authors.initials: A
authors.lastname: Plesa
authors.affiliation: Laboratoire d'Hématologie, CHU de Caen, Caen, France.
authors.forename: Véronique
authors.initials: V
authors.lastname: Salaun
authors.affiliation: Laboratoire d'Immunologie, CHU de Nancy, Nancy, France.
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Béné
authors.affiliation: Laboratoire d'Hématologie, CHU Henri Mondor, Créteil, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Bories
authors.affiliation: Hématologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Tournilhac
authors.affiliation: Laboratoire d'Hématologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
authors.forename: Hélène
authors.initials: H
authors.lastname: Merle-Béral
authors.affiliation: Hématologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.|Sorbonne Universités, UPMC Univ Paris 06, GRC n°11, GRECHY, Paris, France.
authors.forename: Véronique
authors.initials: V
authors.lastname: Leblond
authors.affiliation: Laboratoire d'Hématologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
authors.forename: Magali
authors.initials: M
authors.lastname: Le Garff-Tavernier
authors.affiliation: Hématologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.|Unité d'Hématologie Adolescents Jeunes Adultes, Hôpital Saint-Louis, Paris, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Dhedin
mesh_terms: D064591:Allografts; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual; D015996:Survival Rate
keywords: allogeneic transplantation; chronic lymphocytic leukemia; flow cytometry; minimal residual disease